The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face ...

The quarter's results, reaffirmed Bristol Myers Squibb's financial health and strategic focus despite ongoing competition from generics manufacturers impacting its legacy portfolio of drugs.

Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.67 per share, beating the Zacks Consensus Estimate of $1.46 per share. This compares to earnings of $1.70 per share a year ago.

Welcome to the Bristol Myers Squibb fourth quarter 2024 earnings conference call. [Operator instructions] Please note this event is being recorded. I would now like to turn the conference over to ...

Citi analyst Geoff Meacham maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target of $65.00. The company’s shares closed yesterday at $57.42.

Shares in Bristol-Myers Squibb traded about 2.7% lower Thursday after the drug maker gave 2025 guidance that undershot expectations. Bristol expects sales of about $45.5 billion in 2025 ...

Bristol Myers Squibb posted Q4 revenue of $12.34B, beating the consensus, with an 8% YoY increase driven by Growth Portfolio and Eliquis. Adjusted EPS was $1.67, topping the $1.46 consensus but ...

Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and broad Medicaid/Medicare coverage, supporting its blockbuster potential in schizophrenia and future label expansions.

Bristol Myers Squibb said it has received positive results for its latest lymphoma treatment trials, the fifth type of cancer the drug has been shown to treat. The biopharmaceutical company said ...

BRISTOL-MYERS SQUIBB ($BMY) posted quarterly earnings results on Thursday, February 6th. The company reported earnings of $1.67 per share, beating estimates of $1.47 ...

Pharma giant Bristol Myers Squibb is planning another round of cost cutting as part of a broader restructuring plan. Under the “strategic productivity initiative” announced Feb. 6, the ...

Bristol Myers Squibb said it will slash $2 billion in costs by the end of 2027, expanding its ongoing cost-savings effort to chart a path toward long-term growth. The company also issued full ...